Jairath V. Late-breaker: First and only treat-to-target study in ulcerative colitis. Presented at: United European Gastroenterology Week; Oct. 17-20, 2026; Barcelona, Spain.
Disclosures:
Jairath reports receiving consulting, advisory board or speaker fees from AbbVie, Alimentiv, Amgen, Anaptys Bio, Asahi Kasei, Asieris, AstraZeneca, Attova, Blackbird Labs, BMS, Boehringer Ingelheim, Biomebank, Cabaletta, Caldera, Calluna, Catalytic Health, Celltrion, Eli Lilly, Ensho, Enthera, Enveda, Exeliome Biosciences,Ferring, Fresenius Kabi, Gilead Sciences, Granite Bio, GlaxoSmithKline, Janssen, Merck, Mobius, Mountainfield, MRM Health, Nxera, Orbimed, organon, OSE Immunotherapeutics, Palisade Bio, Pendopharm, Pfizer, PharmaNest, Pioneering Medicine, PIPr Therapeutics, Roche/Genentech, Sanofi, SCOPE, Shattuck Labs, Sorriso, Spyre Therapeutics, Synedgen, Takeda, Teva, Tillotts Pharma AG, Throne Scientific, Tr1X Inc., Union Therapeutics, Ventus, Ventyx, Vividion, Xencor and Zealand Pharma.
